Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan

被引：3
|
作者：
Yun, Karen M. [1 ]
Bazhenova, Lyudmila [1 ]
机构：
[1] UC San Diego Hlth, Div Hematol Oncol, Moores Canc Ctr, La Jolla, CA 92122 USA
来源：
BMJ CASE REPORTS | 2023年 / 16卷 / 05期
关键词：
Lung cancer (oncology); Therapeutic indications; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HER2; GENE; IMMUNOHISTOCHEMISTRY; EXPRESSION; HER-2/NEU; SURVIVAL; MUTATION;
D O I：
10.1136/bcr-2022-253260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report
    Zhao, Huan
    Yang, Hongbo
    Yu, Xin
    Feng, Hu
    Yang, Fujun
    ANTI-CANCER DRUGS, 2022, 33 (05) : 509 - 512
  • [22] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [23] Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy
    Desmoulins, Isabelle
    Bellio, Helene
    Mejean, Nathalie
    Truntzer, Caroline
    Ladoire, Sylvain
    EUROPEAN JOURNAL OF CANCER, 2023, 187 : 161 - 163
  • [24] Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue
    Butterbaugh, S. T.
    Patel, R.
    Romond, E. H.
    Mathew, A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3098 - 3099
  • [25] Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S31 - S31
  • [26] Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).
    Sawada, Kentaro
    Okamoto, Wataru
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Yuki, Satoshi
    Yoshino, Takayuki
    Komatsu, Yoshito
    Sakamoto, Naoya
    Fujii, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [27] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
    Smit, E. F.
    Felip, E.
    Uprety, D.
    Nakagawa, K.
    Paz-Ares, L.
    Pacheco, J.
    Li, B. T.
    Planchard, D.
    Baik, C.
    Goto, Y.
    Murakami, H.
    Saltos, A.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Yan, Q.
    Feng, W.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
  • [28] Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
    Kato, Yuki
    Kato, Yasuhiro
    Minegishi, Yuji
    Suzuki, Takahiro
    Nakamichi, Shinji
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Kubota, Kaoru
    Terasaki, Yasuhiro
    Seike, Masahiro
    Gemma, Akihiko
    ONCOTARGETS AND THERAPY, 2021, 14 : 5315 - 5319
  • [29] A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer
    Lazaratos, Anna-Maria
    Bian, David J. H.
    Petrecca, Kevin
    Guiot, Marie-Christine
    Dankner, Matthew
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3824 - 3830
  • [30] Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers.
    DeMatteo, Raymond
    Goldman, Debra A.
    Lin, Sabrina T.
    Buonocore, Darren J.
    Gao, JianJiong
    Chang, Jason C.
    Rekhtman, Natasha
    Offin, Michael
    Yu, Helena Alexandra
    Isbell, James M.
    Jones, David Randolph
    Rudin, Charles M.
    Travis, William D.
    Kris, Mark G.
    Drilon, Alexander E.
    Arcila, Maria E.
    Ginsberg, Michelle S.
    Iasonos, Alexia
    Liu, Dazhi
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345